Navigation Links
Axial Biotech Launches Genetic Test for Adolescent Idiopathic Scoliosis (AIS)
Date:12/9/2008

New assay is the first of its kind to determine likelihood of spinal disease progression

SALT LAKE CITY, Dec. 9 /PRNewswire/ -- Axial Biotech, Inc. announced today the commercial launch of a new DNA-based test that indicates the likelihood of progression to a severe curve for children diagnosed with Adolescent Idiopathic Scoliosis (AIS). This new molecular diagnostic tool marks a major advancement in which medical treatments can be personalized to patients diagnosed with this deforming disease. The test will be marketed under the name of ScoliScore(TM) AIS Prognostic Test.

Scoliosis is an abnormal curvature of the spine that affects two to three percent of the population, or an estimated 7 million people in the United States. Most often scoliosis is identified during school or sport screenings. Girls are eight times more likely than boys to have a curve progress to a point that treatment is required.

Currently, to determine whether or not a curve will progress patients are observed over a period of several years with the uncertainty of not knowing what the long-term outcome is likely to be. If the curve does continue to progress, the most widely accepted treatments are spinal bracing or ultimately spinal fusion surgery.

"For decades, spine surgeons have been looking for ways to determine which patients may progress and which may not," stated Ken Ward, M.D., Chief Scientific Officer for Axial Biotech. "Currently, most patients diagnosed with scoliosis have spinal x-rays repeated over several years because of the lack of precise clinical indicators or markers that can identify the likelihood of severe curve progression. This lack of predictive information is very inefficient and can cause adolescents to be given years of unnecessary radiation exposure."

ScoliScore(TM) was developed by utilizing a genome wide association study that identified a panel of 53 genetic markers associated with severe curve progression. This scoliosis research involved collecting DNA samples from over 9,500 patients from 85 clinical sites throughout the world. The test was then further validated in two separate clinical trials.

John Climaco, CEO and President of Axial Biotech, said that the launch of ScoliScore(TM) illustrates the company's commitment to making critical information from molecular diagnostic tests more broadly available to spinal surgeons, patients, and their family members. "Our long-term vision is to utilize the knowledge and capabilities gained from the development of this test and apply it to other spinal diseases," said Mr. Climaco.

The initial launch of the ScoliScore(TM) test will be to a small group of physicians in the U.S. The test will be processed solely at Axial's CLIA certified laboratory, which meets all applicable state and federal guidelines. It will be made commercially available to physicians nationwide in 2009. Axial Biotech has signed an agreement with DePuy Spine, Inc. to sell and market ScoliScore(TM).

For more information on the ScoliScore(TM) test, please contact Axial Biotech Customer Service at 877-AXIAL98 (877-294-2598) or visit the company's website at www.axialbiotech.com

About Axial Biotech

Axial Biotech, Inc. is the leading developer of molecular diagnostic for common spinal diseases and disorders. Axial is accredited by the College of American Pathologists (CAP) and is certified to comply with the Clinical Laboratory Improvement Amendments (CLIA). Founded in 2002, Axial is based in Salt Lake City, Utah.


'/>"/>
SOURCE Axial Biotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Axial Biotech Appoints Retired Roche Diagnostics Executive to Board
2. Axial Biotech appoints new Vice President of Strategic Initiatives
3. Axial Biotech Names New VP of Reimbursement and Regulatory Affairs
4. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
5. Investor Group Reconfigures Proposed Slate of Replacement Directors for Trinity Biotech
6. The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health
7. Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe
8. Micromet Added to NASDAQ Biotechnology Index
9. Biotech Endorsement Insurance Discount Expanded to Nebraska, Kansas Growers Planting Corn with HERCULEX XTRA Traits
10. Far From Beyond: A Glimpse into the World of Biotechnology and the Future of the Free World
11. North Carolinas Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... 06, 2016 , ... The Center for Excellence in Education (CEE) will sponsor ... on Wednesday February 10, 2016. This Bite of Science session, hosted by the ... at 1500 Remount Road in Front Royal, VA from 5:00 p.m. to 8:00 p.m. ...
(Date:2/5/2016)... 2016  In the pharmaceutical industry the medical affairs ... launch activities including the identification and engagement of key ... especially high in the oncology therapeutic area where most ... the Role of Medical Affairs in Oncology Launch Excellence ... therapies find better ways to utilize medical affairs to ...
(Date:2/5/2016)... 5, 2016 Australian-US drug discovery and development company, ... appointment of a new Chairman, Mr John O,Connor , ... immediately. James Garner , has also been ... former Acting CEO, Mr Iain Ross , will resume ... --> James Garner , has also been formally appointed ...
(Date:2/4/2016)... , Feb. 4, 2016  Sangamo BioSciences, Inc. ... editing, announced today that Edward Lanphier , Sangamo,s ... on the progress of Sangamo,s ZFP Therapeutic ® ... strategy at 2:40 pm ET on Thursday, February 11, ... Global Healthcare Conference. The conference is being held in ...
Breaking Biology Technology:
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
Breaking Biology News(10 mins):